ALLEGAN, Mich., April 13, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to sell and distribute fexofenadine HCl 60 mg and 180 mg tablets; the generic equivalents of Sanofi-Aventis' Allegra 60 mg and 180 mg products. Teva has had Rx approval for these products, and Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation relating to the Allegra brand family of products.
Allegra 60 mg and 180 mg tablets are indicated for the temporary relief of symptoms associated with indoor and outdoor allergies. Chattem, Inc., a wholly-owned U.S. subsidiary of Sanofi-Aventis, launched Allegra 60 mg and 180 mg tablets in retail stores on March 3, 2011 as part of their Rx to OTC switch of the Allegra brand. Perrigo expects to begin distributing fexofenadine 60 mg and 180 mg tablets to its wholesale and retail customers under their store brand labels immediately.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This is a particularly important example of Perrigo's strategic focus and execution of making quality healthcare more affordable to American consumers by introducing new store brand versions of important Rx-to-OTC switch products. We look forward to working with our retail and wholesale customers to grow these new store brand products as important components in their retail allergy categories."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, infant formula, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright©2010 PR Newswire.
All rights reserved